MEK2 (MAP2K2) Rabbit Polyclonal Antibody

CAT#: AP02552PU-S

MEK2 (MAP2K2) rabbit polyclonal antibody, Aff - Purified

Size: 50 ul 100 ul



Need it in bulk or conjugated?
Get a free quote

CNY 1,400.00


货期*
2周

规格
    • 50 ul

Product images

Specifications

Product Data
Applications IHC, WB
Recommend Dilution Western Blot: 1/500-1/1000.
Immunohistochemistry on Paraffin Sections: 1/50-1/100.
Reactivity Human, Mouse, Rat
Host Rabbit
Clonality Polyclonal
Immunogen Peptide sequence around aa.392~396 (P-G-T-P-T) derived from Human MEK-2).
Specificity MEK2 antibody detects endogenous levels of total MEK2 protein.
Formulation PBS(without Mg2+ and Ca2+), pH 7.4 containing 150mM NaCl, 0.02% sodium azide and 50% glycerol
State: Aff - Purified
State: Liquid purified IgG fraction
Concentration lot specific
Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Conjugation Unconjugated
Storage Condition Upon receipt, store undiluted (in aliquots) at -20°C.
Avoid repeated freezing and thawing.
Predicted Protein Size 44 kDa
Gene Name mitogen-activated protein kinase kinase 2
Background Microtubule associated protein kinase kinase 2 (MEK2 or MAPKK2) is a member of a family of tyrosine/threonine protein kinases that activate the ERK 1 & 2/MAPK enzymes by phosphorylating both residues within the threonine/glutamic acid/tyrosine (TEY) motif in the activation loop. MEK 1 & 2 are also activated by dual phosphorylation, which occurs on serines 218 and 222, in the activation loop of the MEKs. Threonine 394 of MEK2 is phosphorylated by ERK 2, which serves as a negative feedback loop by suppressing activation of MEK2.
Synonyms MAP kinase kinase 2, ERK activator kinase 2, MAPK/ERK kinase 2, MEK2, MKK2, MAP kinase kinase 2
Reference Data
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...